肝癌肝移植降期治疗的研究进展  

Progress on Downstaging Treatment of Liver Transplantation after Hepa⁃tocellular Carcinoma

作　　者：高晨豪 杨喆 GAO Chenhao;YANG Zhe(Graduate Academy,Zhejiang Chinese Medical University,Hangzhou,Zhejiang,310053,China;Department of Hepatobiliary and Pancreatic Surgery,Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province,Shulan(Hangzhou)Hospital,Shulan International Medical College,Zhejiang Shuren University,Hangzhou,Zhejiang,310022,China)

机构地区：[1]浙江中医药大学研究生院,浙江杭州310053 [2]浙江树人大学树兰国际医学院树兰(杭州)医院浙江省人工器官与计算医学重点实验室肝胆胰外科,浙江杭州310022

出　　处：《中外医疗》2024年第34期194-198,共5页China & Foreign Medical Treatment

基　　金：浙江省科技计划项目“尖兵”“领雁”研发攻关计划(2024C03149,2023C03046)。

摘　　要：肝移植作为治疗肝细胞肝癌的一种有效治疗方法,为不可切除肝细胞肝癌患者带来了新的希望。然而仍有许多超过移植标准的患者无法通过肝移植有效改善预后,降期治疗作为一种重要的治疗策略为上述患者提供了新的治疗策略。本综述以发表的文献作为基础,详细阐述不同降期治疗方案,如经导管肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)、钇-90微球经导管动脉放射栓塞(transarterial radio-embolization,TARE)、经皮乙醇注射(percutaneous ethanol injection,PEI)和肝癌射频消融术(radiofrequency ab-lation,RFA)等的基本治疗机制、适应证、禁忌证及纳排标准,以及不同降期治疗方案间的利弊和选择时机。Liver transplantation,as an effective treatment for hepatocellular carcinoma,has brought new hope to pa-tients with unresectable hepatocellular carcinoma.However,there are still many patients who exceed the transplanta-tion criteria and cannot effectively improve their prognosis through liver transplantation.Downward treatment,as an important treatment strategy,provides a new treatment strategy for these patients.This review is based on published literature and provides a detailed explanation of the basic treatment mechanisms,indications,contraindications,and inclusion/exclusion criteria for different downgrading treatment regimens,such as transcatheter arterial chemoemboli-zation(TACE),yttrium-90 microsphere transarterial radioembolization(TARE),percutaneous ethanol injection(PEI),and radio frequency ablation(RFA),as well as the advantages,disadvantages,and timing of different downgrading treatment regimens.

关 键 词：肝癌 肝移植 降期治疗 

分 类 号：R4[医药卫生—临床医学]